Reig Jofre Posts Strong Growth in First Semester 2024

LABORATORIO REIG JOFRE (ES:RJF) has released an update.

Reig Jofre, a Spanish pharmaceutical company, reports a robust first semester in 2024 with a 10% revenue increase to 173 million euros and a 13% EBITDA rise, driven by strong demand for antibiotics, dermatological products, and the Forté Pharma brand. The company’s international business, particularly in European markets, strengthens, making up 56% of total revenue, and a significant 30% growth in operating profit is achieved. Industrial investments have been made to enhance productivity at the Toledo and Barcelona plants, with a focus on technological specialization and higher margins.

For further insights into ES:RJF stock, check out TipRanks’ Stock Analysis page.